The management of superficial bladder cancer

M. S. Soloway

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Superficial bladder cancer includes tumors confined to the mucosa and lamina propria. They may be papillary or sessile. Tumors confined to the mucosa include papillomas, papillary carcinomas, or carcinoma in situ. Therapy must be individualized for each patient taking into consideration the histologic type, cytologic grade, location, number, prior history, and presence of atypia or carcinoma in situ in other areas of the bladder. Although the five-year survival rates are good (62-88 percent), the 48-70 percent incidence of subsequent tumors requires constant surveillance. This high incidence is primarily due to the multifocal origin of urothelial tumors, but implantation of tumor cells following local resection may be a contributing factor. Current efforts to reduce this recurrence rate emphasize intravesical chemotherapy. Thio-tepa and epodyl are effective in eradicating one-third of tumors when used for definitive therapy. Most studies demonstrate a reduction in the recurrence rate when they are initiated following endoscopic resection of all visible tumor. A number of other drugs are being investigated for both definitive and prophylactic intravesical chemotherapy. Surgical procedures consist of transurethral resection, transvesical radium implantation, segmental cystectomy, and cystoprostatectomy. Each procedure has its own indications, and the surgeon must be discriminating in their use.

Original languageEnglish
Pages (from-to)1856-1865
Number of pages10
JournalCancer
Volume45
Issue number7 Suppl
StatePublished - Jan 1 1980

Fingerprint

Urinary Bladder Neoplasms
Neoplasms
Mucous Membrane
Carcinoma in Situ
Ethoglucid
Thiotepa
Recurrence
Drug Therapy
Radium
Papillary Carcinoma
Cystectomy
Incidence
Papilloma
Urinary Bladder
Survival Rate
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Soloway, M. S. (1980). The management of superficial bladder cancer. Cancer, 45(7 Suppl), 1856-1865.

The management of superficial bladder cancer. / Soloway, M. S.

In: Cancer, Vol. 45, No. 7 Suppl, 01.01.1980, p. 1856-1865.

Research output: Contribution to journalArticle

Soloway, MS 1980, 'The management of superficial bladder cancer', Cancer, vol. 45, no. 7 Suppl, pp. 1856-1865.
Soloway MS. The management of superficial bladder cancer. Cancer. 1980 Jan 1;45(7 Suppl):1856-1865.
Soloway, M. S. / The management of superficial bladder cancer. In: Cancer. 1980 ; Vol. 45, No. 7 Suppl. pp. 1856-1865.
@article{e50b60970fa4484ea5853a3fe824f8c4,
title = "The management of superficial bladder cancer",
abstract = "Superficial bladder cancer includes tumors confined to the mucosa and lamina propria. They may be papillary or sessile. Tumors confined to the mucosa include papillomas, papillary carcinomas, or carcinoma in situ. Therapy must be individualized for each patient taking into consideration the histologic type, cytologic grade, location, number, prior history, and presence of atypia or carcinoma in situ in other areas of the bladder. Although the five-year survival rates are good (62-88 percent), the 48-70 percent incidence of subsequent tumors requires constant surveillance. This high incidence is primarily due to the multifocal origin of urothelial tumors, but implantation of tumor cells following local resection may be a contributing factor. Current efforts to reduce this recurrence rate emphasize intravesical chemotherapy. Thio-tepa and epodyl are effective in eradicating one-third of tumors when used for definitive therapy. Most studies demonstrate a reduction in the recurrence rate when they are initiated following endoscopic resection of all visible tumor. A number of other drugs are being investigated for both definitive and prophylactic intravesical chemotherapy. Surgical procedures consist of transurethral resection, transvesical radium implantation, segmental cystectomy, and cystoprostatectomy. Each procedure has its own indications, and the surgeon must be discriminating in their use.",
author = "Soloway, {M. S.}",
year = "1980",
month = "1",
day = "1",
language = "English",
volume = "45",
pages = "1856--1865",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "7 Suppl",

}

TY - JOUR

T1 - The management of superficial bladder cancer

AU - Soloway, M. S.

PY - 1980/1/1

Y1 - 1980/1/1

N2 - Superficial bladder cancer includes tumors confined to the mucosa and lamina propria. They may be papillary or sessile. Tumors confined to the mucosa include papillomas, papillary carcinomas, or carcinoma in situ. Therapy must be individualized for each patient taking into consideration the histologic type, cytologic grade, location, number, prior history, and presence of atypia or carcinoma in situ in other areas of the bladder. Although the five-year survival rates are good (62-88 percent), the 48-70 percent incidence of subsequent tumors requires constant surveillance. This high incidence is primarily due to the multifocal origin of urothelial tumors, but implantation of tumor cells following local resection may be a contributing factor. Current efforts to reduce this recurrence rate emphasize intravesical chemotherapy. Thio-tepa and epodyl are effective in eradicating one-third of tumors when used for definitive therapy. Most studies demonstrate a reduction in the recurrence rate when they are initiated following endoscopic resection of all visible tumor. A number of other drugs are being investigated for both definitive and prophylactic intravesical chemotherapy. Surgical procedures consist of transurethral resection, transvesical radium implantation, segmental cystectomy, and cystoprostatectomy. Each procedure has its own indications, and the surgeon must be discriminating in their use.

AB - Superficial bladder cancer includes tumors confined to the mucosa and lamina propria. They may be papillary or sessile. Tumors confined to the mucosa include papillomas, papillary carcinomas, or carcinoma in situ. Therapy must be individualized for each patient taking into consideration the histologic type, cytologic grade, location, number, prior history, and presence of atypia or carcinoma in situ in other areas of the bladder. Although the five-year survival rates are good (62-88 percent), the 48-70 percent incidence of subsequent tumors requires constant surveillance. This high incidence is primarily due to the multifocal origin of urothelial tumors, but implantation of tumor cells following local resection may be a contributing factor. Current efforts to reduce this recurrence rate emphasize intravesical chemotherapy. Thio-tepa and epodyl are effective in eradicating one-third of tumors when used for definitive therapy. Most studies demonstrate a reduction in the recurrence rate when they are initiated following endoscopic resection of all visible tumor. A number of other drugs are being investigated for both definitive and prophylactic intravesical chemotherapy. Surgical procedures consist of transurethral resection, transvesical radium implantation, segmental cystectomy, and cystoprostatectomy. Each procedure has its own indications, and the surgeon must be discriminating in their use.

UR - http://www.scopus.com/inward/record.url?scp=0018840343&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018840343&partnerID=8YFLogxK

M3 - Article

C2 - 6768441

AN - SCOPUS:0018840343

VL - 45

SP - 1856

EP - 1865

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 7 Suppl

ER -